Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
Go back to Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study| (NASDAQ: ACON) | Delayed: 2.71 -0.03 (1.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.74 | 52 Week High | $ | |||
| Open | $2.72 | 52 Week Low | $ | |||
| Day High | $2.78 | P/E | N/A | |||
| Day Low | $2.62 | EPS | $ | |||
| Volume | 83,764 | |||||
| (NASDAQ: ACONW) | Delayed: 0.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.03 | 52 Week High | $ | |||
| Open | $0.03 | 52 Week Low | $ | |||
| Day High | $0.03 | P/E | N/A | |||
| Day Low | $0.02 | EPS | $ | |||
| Volume | 15,165 | |||||
